The short answer

Regenerative medicine has the strongest evidence for knee osteoarthritis — a 2021 meta-analysis of 9 RCTs with 476 patients found mesenchymal stem cells reduced knee-OA pain versus controls (Qu & Sun, 2021). Evidence is thinner for back, shoulder, hip, tendon, and nerve conditions, and almost none of these uses is FDA-approved.

The honest framing: MSC and PRP therapies are investigational for nearly every orthopedic condition. Candidacy, diagnosis, and realistic expectations must come from a licensed physician — not a marketing page.

Regenerative medicine — including mesenchymal stem cell (MSC) and platelet-rich plasma (PRP) therapies — is studied across a range of musculoskeletal and chronic pain conditions. The depth of evidence differs a lot by condition: it is strongest for the knee and thinner elsewhere. Below is a plain-language overview of where these approaches are most commonly explored, followed by a closer look at what the research actually supports for each. Throughout, remember that many of these uses are investigational and not FDA-approved, and only a licensed provider can determine whether any treatment is appropriate for you.

Joint, spine and nerve conditions

PRP for joints, hair and skin

Platelet-rich plasma uses your own blood, prepared in the office. It is used for joints and for several aesthetic concerns.

What treatment costs

Prices from published U.S. studies where they exist, and clearly labeled estimates where they don’t.

What the evidence says, condition by condition

Knee pain & osteoarthritis

The knee is the most studied joint in regenerative medicine. A 2021 meta-analysis of nine randomized controlled trials of stem cell therapy for knee osteoarthritis reported improvements in some pain and function scores — an encouraging signal — though the authors cautioned that the trials were small and varied, and that larger, longer studies are still needed. It is reasonable to consider regenerative options before irreversible surgery, with a physician's input. Read more: Stem cell therapy for knee pain.

Back & spine pain

Research into MSCs for degenerative disc disease and chronic low-back pain is growing but earlier-stage, based largely on smaller studies. Early results for discogenic pain are promising but not conclusive. Related reading: stem cells and back injuries.

Shoulder pain

Evidence for the shoulder — rotator cuff injuries, labral issues, and osteoarthritis — is emerging, with a smaller but increasing body of research compared with the knee. Treatment is investigational and outcomes vary. Read more: stem cell therapy for shoulder pain.

Hip pain

The hip has fewer high-quality studies than the knee. Regenerative approaches are sometimes explored for hip osteoarthritis, bursitis, and labral pathology as a non-surgical option to evaluate with a qualified provider. Read more: stem cell therapy for hip pain.

Arthritis & joint inflammation

Much of the interest in MSCs centers on their anti-inflammatory and immunomodulatory signaling rather than wholesale tissue regrowth. This helps explain why some patients report relief even when imaging shows limited structural change — and why "guaranteed cartilage regrowth" claims should be viewed skeptically. Read more: stem cell therapy for arthritis & osteoarthritis.

Neuropathy

Certain types of peripheral neuropathy and nerve-related pain are being investigated, but candidacy varies widely and the evidence is early. A thorough physician evaluation is essential before considering any regenerative approach here. Read more: stem cell therapy for neuropathy.

Joint degeneration & soft-tissue injuries

Tendon, ligament, and soft-tissue injuries are often studied alongside platelet-rich plasma (PRP), with mixed and limited results to date. These are typically considered when conservative care has not helped and surgery is on the table.

For a deeper, fully sourced review, see our MSC research for orthopedic pain pillar and our complete guide to stem cell research. To understand the regulatory picture, see our guide to FDA approval and safety of stem cell therapy.

Conditions FAQ

Generally, no. The FDA states that regenerative products such as stem cells, exosomes, adipose-derived products, Wharton's jelly, cord blood, and amniotic fluid have not been approved to treat orthopedic conditions including osteoarthritis, tendonitis, disc disease, and back, hip, knee, neck, and shoulder pain. The FDA-approved stem cell products are limited to blood-forming cells derived from umbilical cord blood, approved for blood-production disorders, and a few other cell products for blood cancers and transplant complications. Many orthopedic uses remain investigational.
Knee osteoarthritis has the most research to date. A 2021 meta-analysis of nine randomized controlled trials reported improvements in some pain and function scores, though the trials were small and varied in design, so results are considered promising but not conclusive.
Only a licensed physician can determine candidacy after evaluating your condition, imaging, and medical history. Our free assessment helps match you with a verified clinic that can perform that evaluation.
No. Outcomes vary by individual and are not guaranteed. Be cautious of any provider that promises a guaranteed cure or specific result.
Knee pain, back and spine pain, shoulder pain, hip pain, arthritis and joint inflammation, neuropathy, joint degeneration, and soft-tissue injuries are the conditions most often explored for regenerative options.
Most regenerative treatments for these conditions are not currently covered by insurance. Clinics often offer financing or payment plans; confirm costs directly with the provider.
Now Accepting New Patients

Not Sure If You're a Candidate?

Complete a brief assessment and we'll match you with a board-certified, verified clinic in your area to discuss your specific condition.

Begin Your Assessment